Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
Postprint
DOI
PMC
 |
Open Access Green |
möglich sobald bei der ZB eingereicht worden ist.
Utilizing chemokines in cancer immunotherapy.
Trends Cancer 8, 670-682 (2022)
Immune checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy have demonstrated stunning clinical efficacy in many cancer types. However, most patients do not respond to immunotherapies or relapse after an initial response, stressing the need for improved strategies. Chemokines, as mediators of immune cell trafficking, play an important role in the composition of the tumor microenvironment and exert both pro- and antitumorigenic functions. Here, chemokines may represent valuable prognostic biomarkers of response to immunotherapy and a strategy to improve immunotherapies. In this review, the pleiotropic functions of chemokines in the tumor microenvironment (TME) and strategies of utilizing chemokines or chemokine antagonism in immunotherapy are discussed. The review highlights preclinical and clinical studies that apply or target chemokines in monotherapy or in combination therapies.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Car T Cells ; Antibodies ; Cancer Vaccines ; Chemokines ; Inhibitors ; Oncolytic Viruses
ISSN (print) / ISBN
2405-8033
e-ISSN
2405-8025
Zeitschrift
Trends in cancer
Quellenangaben
Band: 8,
Heft: 8,
Seiten: 670-682
Verlag
Elsevier
Verlagsort
Amsterdam
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Unit for Clinical Pharmacology (KKG-EKLiP)